← FDA DRUG APPROVALS

FDA ANDA · ANDA091654

VALSARTAN; HYDROCHLOROTHIAZIDE

Sponsor: TORRENT PHARMS LTD

APPLICATION
ANDA091654
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)

Products

VALSARTAN; HYDROCHLOROTHIAZIDENone (Tentative Approval)
VALSARTAN 320MG, HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL
VALSARTAN; HYDROCHLOROTHIAZIDENone (Tentative Approval)
VALSARTAN 160MG, HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL
VALSARTAN; HYDROCHLOROTHIAZIDENone (Tentative Approval)
VALSARTAN 80MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL
VALSARTAN; HYDROCHLOROTHIAZIDENone (Tentative Approval)
VALSARTAN 320MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL
VALSARTAN; HYDROCHLOROTHIAZIDENone (Tentative Approval)
VALSARTAN 160MG, HYDROCHLOROTHIAZIDE 12.5MG · TABLET · ORAL

Approval history

2012-04-10OriginalTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →